🔗 Permalink

Inventor profile of:

Robin Steigerwald

City:

Munich

Country:

Germany

Published Applications:

Last publication date:

2026-03-19

Top Assignees for applications by Robin Steigerwald

The entities that hold a legal rights for patent applications filed by inventor Steigerwald Robin:

BAVARIAN NORDIC A/S 26 KVISTGAARD, Denmark
Bavarian Nordic A/S 8 Hellerup, Denmark
Janssen Vaccines & Prevention B.V. 5 Leiden, Netherlands
The United States of America, as represented by the Secretary, Department of Health and Human Services 3 Bethesda, MD United States
Janssen Vaccines & Prevention B.V. 1 Leiden, Netherlands
The United States of America, as represented by the Secretary, Department of Health and Human Ser. 1 Bethesda, MD United States
Bavarian Nordic A/S 1 Kvisgaard, Denmark
The United States of America as represented by the Secretary, Department of Health and Human Service 1 Bethesda, MD United States

Recent patent applications by Steigerwald Robin

Robin Steigerwald from Munich, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-03-19

US20260078353A1

Chemistry; metallurgy

Mammalian Cell Line for the Production of Modified Vaccinia Virus Ankara (MVA)

#2 | 2025-12-25

US20250387463A1

Human necessities

Recombinant Modified saRNA (VRP) and Vaccinia Virus Ankara (MVA) Prime-Boost Regimen

#3 | 2023-07-27

US20230233670A1

Human necessities

A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease

#4 | 2022-03-24

US20220088170A1

Human necessities

Methods and compositions for inducing protective immunity against filovirus infection

#5 | 2021-12-23

US20210393766A1

Human necessities

Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine

#6 | 2021-07-08

US20210205439A1

Human necessities

Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine

#7 | 2021-07-01

US20210196814A1

Human necessities

Recombinant Modified Vaccinia Virus Ankara (MVA) Respiratory Syncytial Virus (RSV) Vaccine

#8 | 2020-08-27

US20200268872A1

Human necessities

Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens

#9 | 2020-06-04

US20200171142A1

Human necessities

Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

#10 | 2020-02-06

US20200038500A1

Human necessities

Methods and compositions for inducing protective immunity against filovirus infection

#11 | 2019-07-25

US20190224301A1

Human necessities

Methods and compositions for inducing protective immunity against a marburg virus infection

#12 | 2019-04-25

US20190117764A1

Human necessities

Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

#13 | 2019-02-21

US20190055582A1

Chemistry; metallurgy

Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity

#14 | 2019-02-07

US20190038739A1

Human necessities

Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine

#15 | 2018-07-05

US20180185466A1

Human necessities

Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine

#16 | 2018-04-26

US20180111966A1

Chemistry; metallurgy

PR13.5 promoter for robust T-cell and antibody responses

#17 | 2017-11-30

US20170340721A1

Human necessities

Methods and compositions for enhancing immune responses

#18 | 2017-11-16

US20170326228A1

Human necessities

Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine

#19 | 2017-10-26

US20170304427A1

Human necessities

Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use

#20 | 2017-10-12

US20170290904A1

Human necessities

Methods and compositions for inducing protective immunity against filovirus infection

#21 | 2017-07-27

US20170211098A1

Chemistry; metallurgy

Vector comprising multiple homologous nucleotide sequences

#22 | 2017-05-11

US20170128561A1

Human necessities

Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus

#23 | 2017-03-23

US20170081642A1

Chemistry; metallurgy

RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT C

#24 | 2017-02-16

US20170043008A1

Human necessities

Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

#25 | 2016-01-21

US20160017369A1

Chemistry; metallurgy

Vector comprising multiple homologous nucleotide sequences

#26 | 2015-10-22

US20150299267A1

Chemistry; metallurgy

Pr13.5 promoter for robust T-cell and antibody responses

#27 | 2015-07-30

US20150209421A1

Human necessities

Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

#28 | 2015-06-25

US20150174238A1

Human necessities

Poxviral vectors for low antibody response after a first priming immunization

#29 | 2014-11-20

US20140342403A1

Chemistry; metallurgy

PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION

#30 | 2014-10-30

US20140322265A1

Human necessities

Recombinant poxvirus vector comprising tetanus toxin fragment C

#31 | 2012-05-17

US20120121617A1

Chemistry; metallurgy

Promoters for recombinant viral expression

#32 | 2011-09-29

US20110236976A1

Chemistry; metallurgy

Vector comprising multiple homologous nucleotide sequences

InventorID:

952788 ⎘